Cardiovascular risk profile of antirheumatic agents in patients with osteoarthritis and rheumatoid arthritis

Drugs

Volumn 62, Issue 11, 2002, Pages 1599-1609

  Nurmohamed, Michael T ^a,b   van Halm, Vokko P ^a,b   Dijkmans, Ben A C ^a,b,c  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b JAN VAN BREEMEN INSTITUTE   (Netherlands)

^c SLOTERVAART HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTIRHEUMATIC AGENT; CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; ETANERCEPT; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INFLIXIMAB; LEFLUNOMIDE; NONSTEROID ANTIINFLAMMATORY AGENT;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONGESTIVE HEART FAILURE; DRUG CONTRAINDICATION; DRUG INDICATION; EDEMA; GASTROINTESTINAL TOXICITY; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; OSTEOARTHRITIS; PRACTICE GUIDELINE; REVIEW; RHEUMATOID ARTHRITIS;

EID: 0036328556     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200262110-00003     Document Type: Review

References (70)

1. Incidence of symptomatic hand, hip, and knee osteoarthritis among patients in a health maintenance organization
2. Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 Update
3. The verdict favors nonsteroidal antiinflammatory drugs for treatment of osteoarthritis and a plea for more evidence on other treatments
4. A randomised, double-blind, crossover clinical trial of diclofenac plus misoprostol versus acetaminophen in patients with osteoarthritis of the hip or knee
5. Gastrointestinal toxicity of nonsteroidal anti-inflammatory drugs
6. A comparison of omeprazol with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs
7. Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs
8. Rheumatoid arthritis: Clinical aspects and its variants
9. Guidelines for the management of rheumatoid arthritis
10. Current treatment paradigms in rheumatoid arthritis
11. Methotrexate
12. Rheumatoid arthritis: Treatment of early disease
13. Systemic low-dose glucocorticoid in rheumatoid arthritis
14. Rheumatoid arthritis
15. Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen and naprxen on COX-2 versus COX-1 in healthy volunteers
16. Beyond willow bark: Aspirin in the prevention of chronic disease
17. Cox-2-selective NSAIDs: New and improved?
18. Augmented expression of cyclooxygenase-2 in human atherosclerotic lesions
19. Identification of vascular endothelial genes differentially responsive to fluid mechanical: Cyclooxygenase-2, manganese superoxide dismutase, and endothelial nitric oxide synthase are selectively up-regulated by steady laminar shear stress
20. Risk of cardiovascular events associated with selective COX-2 inhibitors
21. The coxibs, selective inhibitors of cyclooxygenase-2
22. Cyclooxygenase inhibition and thrombogenicity
23. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis
24. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: The class study: A randomised controlled trial
25. Differential effects of aspirin and nonaspirin nonsteroidal antiinflammatory drugs in the primary prevention of myocardial infarction in postmenopausal women
26. Platelet active drugs: The relationships among dose, effectiveness, and side effects
27. FDA warns Merck over its promotion of rofecoxib
28. NSAIDs and selective COX-2 inhibitors: Competition between gastroprotection and cardioprotection
29. Prevention of post-discharge venous thromboembolism in patients with rheumatoid arthritis undergoing knee or hip arthroplasty: A continuing matter of debate
30. Renal and related cardiovascular effects of conventional and COX-2-specific NSAIDs and non-NSAID analgesics
31. The impact of nonsteroidal anti-inflammatory drugs on hypertension: Alternative analgesics for patients at risk
32. Nonsteroidal anti-inflammatory drugs and hypertension: The risk in perspective
33. Cyclooxygenase-2-specific inhibitors and cardiorenal function: A randomized, controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients
34. Cyclooxygenase-2-specific inhibitors: Are they safe?
35. A clinical trial comparing rofecoxib to celcoxib and acetaminophen in the treatment of osteoarthritis (OA): Early efficacy results
36. Drug induced heart failure
37. Sulindac: A potential renal-sparing nonsteroidal anti-inflammatory drug
38. Therapeutic implications associated with renal studies of nabumetone
39. Are there differences among nonsteroidal antiinflammatory drugs?: Comparing acetylated salicylates, nonacetylated salicylates and nonacetylated nonsteroidal antiinflammatory drugs
40. Differences in NSAID tolerability profiles: Fact or fiction?
41. Consumption of NSAIDs and the development of congestive heart failure in elderly patients
42. Cox-2-specific inhibitors: The emergence of a new class analgesic and anti-inflammatory drugs
43. Renal effects of selective cyclooxygenase inhibition in normotensive salt-depleted subjects
44. Effect of cyclooxygenase-2 inhibition on renal function in elderly persons receiving a low-salt diet: A randomised controlled trial
45. Low dose long-term corticosteroid therapy in rheumatoid arthritis: An analysis of serious adverse events
46. Low-dose corticosteroids in rheumatoid arthritis: A meta-analysis of their moderate-term effectiveness
47. Relationship between corticosteroid exposure and plasma lipid levels in heart transplant patients
48. Effects of deflazacort versus prednisone on bone mass, body compositioin, and lipid profile: A randomised double blind study in kidney transplant patients
49. Adverse effects of corticosteroids on the cardiovascular system
50. Does long-term low-dose corticosteroid therapy cause hypertension
51. Randomised comparison of combined step-down prednisolon, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis
52. Serum lipoproteln in active rheumatoid arthritis and other chronic inflammatory arthritides I: Relativity to inflammatory activity
53. Serum lipoprotein in active rheumatoid arthritis and other chronic inflammatory artrtitides II: Effects of anti-inflammatory and disease-modifying drug treatment
54. Cortocosteroids and cholesterol levels in rheumatoid arthritis (RA)
55. Cardiovascular morbidity and mortality in patients with seropositive rheumatoid arthritis in northern Sweden
56. Rheumatoid arthritis is an independent risk factor for ischaemic heart disease
57. Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: A double-blind, randomised, multicentre trial
58. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate
59. Efficacy and safety of leflunomide in active rheumatoid arthritis
60. Treatment of active rheumatoid arthrtitis with leflunomide: Two year follow up of a double blind placebo controlled trial versus sulfasalazine
61. Two-year, blinded, randomised, controlled trial of active rheumatoid arthritis compared with methotrexate: Utilization of leflunomide in the treatment of rheumatoid arthrititis trial investigator group
62. High discontinuation rate of treatment with leflunomide in daily practice
63. TNF-α heart failure: The difference between proof of principle and hypothesis testing
64. Safety and efficacy of a soluble p75 tumor necrosis factor receptor (Enbrel, Etanercept) in patients with advanced heart failure
65. Results of targeted anti-tumor necrosis factor therapy with etanercept (ENBREL) in patients with advanced heart failure
66. Clinical trials update: Capricorn, copernicus, miracle, staf, ritz-2, recover and renaissance and cachexia and cholesterol in heart failure
67. Acetaminophen and other risk factors for excessive warfarin anticoagulation
68. Cardiovascular thrombotic events in controlled clinical trials of rofecoxib
69. Non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease: An observational cohort study